



SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

(Established under the Science Centre Act, Cap. 286)

ANNUAL REPORT

For the financial year ended 31 March 2018

**SCIENCE CENTRE BOARD
AND ITS SUBSIDIARIES**
(Established under the Science Centre Act, Cap. 286)

ANNUAL REPORT
For the financial year ended 31 March 2018

Contents

	Page
Statement by the Board of Science Centre Board	1
Independent Auditors' Report	2
Statement of Comprehensive Income - Group	6
Statement of Comprehensive Income - Board	7
Balance Sheets - Group and Board	8
Statement of Changes in Capital, Funds and Accumulated Surplus - Group	9
Statement of Changes in Capital, Funds and Accumulated Surplus - Board	10
Consolidated Statement of Cash Flows	11
Notes to the Financial Statements	12

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

STATEMENT BY DIRECTORS

For the financial year ended 31 March 2018

In the opinion of Science Centre Board (the "Board"),

- (a) the consolidated financial statements of the Group as set out on pages 6 to 53 are drawn up so as to present fairly, in all material respects, the financial position of the Board and of the Group as at 31 March 2018, and the financial performance of the business, changes in capital, funds and accumulated surplus of the Board and of the Group and cash flows of the Group for the financial year then ended; and
- (b) proper accounting and other records have been kept, including records of all assets of the Group whether purchased, donated or otherwise have been kept in accordance with the provisions of the Science Centre Act, Cap. 286 (the "Act"); and
- (c) the receipts, expenditure, investment of moneys and the acquisition and disposal of assets by the Board during the financial year have been made in accordance with the provisions of the Act.

On behalf of the Board



Ms Tan Yen Yen
Chairman



Associate Professor Lim Tit Meng
Chief Executive

4 June 2018



KPMG LLP
16 Raffles Quay #22-00
Hong Leong Building
Singapore 048581

Telephone +65 6213 3388
Fax +65 6225 0984
Internet www.kpmg.com.sg

Independent auditors' report

Science Centre Board and its Subsidiaries

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Science Centre Board ("the Board") and its subsidiaries ("the Group"), which comprise the consolidated balance sheet of the Group and the balance sheet of the Board as at 31 March 2018, the statements of comprehensive income, and statements of changes in capital, funds and accumulated surplus of the Group and the Board and the consolidated statement of cash flows of the Group for the year then ended, and notes to the financial statements, including a summary of accounting policies, as set out on pages 6 to 53.

In our opinion, the accompanying consolidated financial statements of the Group and the balance sheet, statement of comprehensive income, statement of changes in capital, funds and accumulated surplus of the Board are properly drawn up in accordance with the provisions of the Science Centre Act, Cap. 286 ('the Act') and Statutory Board Financial Reporting Standards ("SB-FRS") so as to present fairly, in all material respects the state of affairs of the Group and the Board as at 31 March 2018 and the results and changes in equity of the Group and the Board and cash flows of the Group for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with Singapore Standards on Auditing ('SSAs'). Our responsibilities under those standards are further described in the '*Auditors' responsibilities for the audit of the financial statements*' section of our report. We are independent of the Group and the Board in accordance with the Accounting and Corporate Regulatory Authority *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* ('ACRA Code') together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Management is responsible for the other information contained in the annual report. Other information is defined as all information in the annual report other than the financial statements and our auditors' report thereon.



We have obtained the Statement by the Board of the Science Centre Board, prior to the date of this auditors' report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditors' report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and the Board of Directors for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the provisions of the Act and SB-FRS, and for such internal control as management determines is necessary to enable preparation of financial statements that are free from material misstatement, whether due to fraud or error.

A statutory board is constituted based on its Act and its dissolution requires Parliaments' approval. In preparing the financial statements, management is responsible for assessing the Board's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless there is intention to wind up the Board or for the Board to cease operations.

The Board of Directors is responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

Report on Other Legal and Regulatory Requirements

In our opinion, proper accounting and other records required by the Act to be kept by the Board and by those subsidiaries incorporated in Singapore, of which we are the auditors, have been properly kept in accordance with the provisions of the Act.



Other Matter

During the course of our audit, nothing came to our attention that caused us to believe that the receipts, expenditure and investment of moneys and the acquisition and disposal of assets by the Board during the financial year have not been made in accordance with the provisions of the Act.

A handwritten signature in black ink, appearing to read 'KPMG' followed by a stylized mark.

KPMG LLP

*Public Accountants and
Chartered Accountants*

Singapore

4 June 2018

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

STATEMENT OF COMPREHENSIVE INCOME

For the financial year ended 31 March 2018

GROUP	Note	General Funds		Restricted Funds		Total	
		2018 \$	2017 \$	2018 \$	2017 \$	2018 \$	2017 \$
Income							
- Admission fees		4,991,956	4,602,383	-	-	4,991,956	4,602,383
- Proceeds from special projects		562,505	1,316,874	-	-	562,505	1,316,874
- Fees from courses and programmes		1,158,564	1,065,300	-	-	1,158,564	1,065,300
- Collections from exhibits and events		704,338	290,684	-	-	704,338	290,684
- Sales of merchandise and publications		998,260	1,222,505	-	-	998,260	1,222,505
- Service income		669,277	417,336	-	-	669,277	417,336
- Rental income		73,142	-	-	-	73,142	-
- Photo-taking income		169,489	203,564	-	-	169,489	203,564
		<u>9,327,531</u>	<u>9,118,646</u>	<u>-</u>	<u>-</u>	<u>9,327,531</u>	<u>9,118,646</u>
Other income	4	2,082,062	1,903,171	1,048,222	1,170,664	3,130,284	3,073,835
Other (losses)/gains - net	5	(488)	(27)	88,803	156,496	88,315	156,469
Expenses							
- Employee compensation	6	(20,705,012)	(21,463,579)	(240,122)	(187,808)	(20,945,134)	(21,651,387)
- Materials for exhibits and events		(9,403,795)	(5,413,305)	(546,492)	(704,965)	(9,950,287)	(6,118,270)
- Repairs and maintenance		(6,311,479)	(5,910,854)	(13,276)	(2,842)	(6,324,755)	(5,913,696)
- Publicity and promotions		(2,569,997)	(2,430,370)	(19,131)	(22,751)	(2,589,128)	(2,453,121)
- Depreciation	16	(3,770,277)	(4,135,552)	(4,600)	(1,178)	(3,774,877)	(4,136,730)
- Other expenditure	7	(4,198,647)	(4,211,527)	(172,698)	(195,931)	(4,371,345)	(4,407,458)
- Finance expenses	8	(1,880)	(586)	-	-	(1,880)	(586)
		<u>(46,961,087)</u>	<u>(43,565,773)</u>	<u>(996,319)</u>	<u>(1,115,475)</u>	<u>(47,957,406)</u>	<u>(44,681,248)</u>
(Deficit)/surplus before grants		(35,551,982)	(32,543,983)	140,706	211,685	(35,411,276)	(32,332,298)
Operating grants from government	17	32,200,552	30,152,938	-	-	32,200,552	30,152,938
Grants from other government agencies	11	3,099,458	1,067,555	-	-	3,099,458	1,067,555
Deferred capital grants amortised	21	1,233,865	1,242,318	4,600	1,178	1,238,465	1,243,496
		<u>36,533,875</u>	<u>32,462,811</u>	<u>4,600</u>	<u>1,178</u>	<u>36,538,475</u>	<u>32,463,989</u>
Surplus/(deficit) before tax		981,893	(81,172)	145,306	212,863	1,127,199	131,691
Income tax credit/(expense)	9	4,474	(3,101)	-	-	4,474	(3,101)
Net surplus/(deficit) and total comprehensive income		986,367	(84,273)	145,306	212,863	1,131,673	128,590

The accompanying notes form an integral part of these financial statements.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

STATEMENT OF COMPREHENSIVE INCOME

For the financial year ended 31 March 2018

BOARD	Note	General Funds		Restricted Funds		Total	
		2018 \$	2017 \$	2018 \$	2017 \$	2018 \$	2017 \$
Income							
- Admission fees		4,022,018	3,501,422	-	-	4,022,018	3,501,422
- Proceeds from special projects		565,082	1,319,642	-	-	565,082	1,319,642
- Fees from courses and programmes		778,153	738,543	-	-	778,153	738,543
- Collections from exhibits and events		711,250	290,684	-	-	711,250	290,684
- Sales of merchandise and publications		787,172	868,083	-	-	787,172	868,083
- Service income		26,049	43,044	-	-	26,049	43,044
		6,889,724	6,761,418	-	-	6,889,724	6,761,418
Other income	4	2,085,641	1,860,005	1,048,222	1,170,664	3,133,863	3,030,669
Other (losses)/gains - net	5	(488)	(27)	88,803	156,496	88,315	156,469
Expenses							
- Employee compensation	6	(19,351,168)	(20,314,636)	(240,122)	(187,808)	(19,591,290)	(20,502,444)
- Materials for exhibits and events		(9,391,365)	(5,403,563)	(602,567)	(759,495)	(9,993,932)	(6,163,058)
- Repairs and maintenance		(5,736,250)	(5,382,891)	(13,276)	(2,842)	(5,749,526)	(5,385,733)
- Publicity and promotions		(2,378,894)	(2,289,193)	(19,131)	(22,751)	(2,398,025)	(2,311,944)
- Depreciation	16	(3,351,033)	(3,698,046)	(4,600)	(1,178)	(3,355,633)	(3,699,224)
- Other expenditure	7	(4,069,242)	(3,652,115)	(172,698)	(195,931)	(4,241,940)	(3,848,046)
- Finance expenses	8	(1,880)	(586)	-	-	(1,880)	(586)
		(44,279,832)	(40,741,030)	(1,052,394)	(1,170,005)	(45,332,226)	(41,911,035)
(Deficit)/surplus before grants		(35,304,955)	(32,119,634)	84,631	157,155	(35,220,324)	(31,962,479)
Operating grants from government	17	32,200,552	30,152,938	-	-	32,200,552	30,152,938
Grants from other government agencies	11	3,076,240	1,055,607	-	-	3,076,240	1,055,607
Deferred capital grants amortised	21	1,201,335	1,204,028	4,600	1,178	1,205,935	1,205,206
		36,478,127	32,412,573	4,600	1,178	36,482,727	32,413,751
Net surplus and total comprehensive income		1,173,172	292,939	89,231	158,333	1,262,403	451,272

The accompanying notes form an integral part of these financial statements.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

BALANCE SHEETS

As at 31 March 2018

	Note	Group		Board	
		2018 \$	2017 \$	2018 \$	2017 \$
ASSETS					
Current assets					
Cash and cash equivalents	10	28,624,938	24,145,695	27,947,422	23,415,119
Trade and other receivables	11	3,424,069	3,674,118	3,452,283	3,715,580
Financial asset at fair value through profit or loss	12	4,317,805	4,229,002	4,317,805	4,229,002
Held-to-maturity financial assets	13	-	1,002,500	-	1,002,500
Inventories	14	397,173	575,750	168,579	205,302
		36,763,985	33,627,065	35,886,089	32,567,503
Non-current assets					
Held-to-maturity financial assets	13	1,018,000	1,018,000	1,018,000	1,018,000
Investments in subsidiaries	15	-	-	1,760,002	1,760,002
Property, plant and equipment	16	22,628,747	25,130,699	21,576,734	23,822,596
		23,646,747	26,148,699	24,354,736	26,600,598
Total assets		60,410,732	59,775,764	60,240,825	59,168,101
LIABILITIES					
Current liabilities					
Government grants received in advance	17	11,204,226	10,153,612	11,204,226	10,153,612
Other government grants received in advance	11	1,990,216	725,188	1,990,216	725,188
Sponsorship received in advance	18	762,156	888,850	762,156	888,850
Trade and other payables	19	4,941,057	7,022,922	4,673,950	6,470,678
Current income tax liabilities	9	-	7,541	-	-
		18,897,655	18,798,113	18,630,548	18,238,328
Non-current liabilities					
Other payables		25,407	-	-	-
Deferred income tax liabilities	20	48,253	55,478	-	-
Deferred capital grants	21	16,116,922	17,269,971	16,027,412	17,147,931
		16,190,582	17,325,449	16,027,412	17,147,931
Total liabilities		35,088,237	36,123,562	34,657,960	35,386,259
NET ASSETS		25,322,495	23,652,202	25,582,865	23,781,842
CAPITAL, FUNDS AND ACCUMULATED SURPLUS					
Capital account	22	2,979,983	2,979,983	2,979,983	2,979,983
Share capital	23	7,959,330	6,969,710	7,959,330	6,969,710
Omni-theatre development fund	25	122,780	122,780	122,780	122,780
Accumulated surplus:					
General funds		6,600,269	6,064,902	7,029,655	6,307,483
Restricted funds	24	7,660,133	7,514,827	7,491,117	7,401,886
Total capital, funds and accumulated surplus		25,322,495	23,652,202	25,582,865	23,781,842

The accompanying notes form an integral part of these financial statements.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

STATEMENTS OF CHANGES IN CAPITAL, FUNDS AND ACCUMULATED SURPLUS

For the financial year ended 31 March 2018

	<u>Capital account</u> \$	<u>Share capital</u> \$	Omni- theatre development fund \$	<u>Accumulated surplus</u>		<u>Total</u> \$
				<u>General funds</u> \$	<u>Restricted funds</u> \$	
GROUP						
2018						
Beginning of financial year	2,979,983	6,969,710	122,780	6,064,902	7,514,827	23,652,202
Issue of new shares (Note 23)	-	989,620	-	-	-	989,620
Total comprehensive (loss)/income	-	-	-	986,367	145,306	1,131,673
Dividends paid	-	-	-	(451,000)	-	(451,000)
End of financial year	<u>2,979,983</u>	<u>7,959,330</u>	<u>122,780</u>	<u>6,600,269</u>	<u>7,660,133</u>	<u>25,322,495</u>
2017						
Beginning of financial year	2,979,983	6,165,076	122,780	6,149,175	7,301,964	22,718,978
Issue of new shares (Note 23)	-	804,634	-	-	-	804,634
Total comprehensive (loss)/income	-	-	-	(84,273)	212,863	128,590
End of financial year	<u>2,979,983</u>	<u>6,969,710</u>	<u>122,780</u>	<u>6,064,902</u>	<u>7,514,827</u>	<u>23,652,202</u>

The accompanying notes form an integral part of these financial statements.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

STATEMENTS OF CHANGES IN CAPITAL, FUNDS AND ACCUMULATED SURPLUS
For the financial year ended 31 March 2018

	<u>Capital account</u> \$	<u>Share capital</u> \$	Omni- theatre development <u>fund</u> \$	<u>Accumulated surplus</u>		<u>Total</u> \$
				<u>General funds</u> \$	<u>Restricted funds</u> \$	
BOARD						
2018						
Beginning of financial year	2,979,983	6,969,710	122,780	6,307,483	7,401,886	23,781,842
Issue of new shares (Note 23)	-	989,620	-	-	-	989,620
Total comprehensive (loss)/income	-	-	-	1,173,172	89,231	1,262,403
Dividends paid	-	-	-	(451,000)	-	(451,000)
End of financial year	2,979,983	7,959,330	122,780	7,029,655	7,491,117	25,582,865
2017						
Beginning of financial year	2,979,983	6,165,076	122,780	6,014,544	7,243,553	22,525,936
Issue of new shares (Note 23)	-	804,634	-	-	-	804,634
Total comprehensive (loss)/income	-	-	-	292,939	158,333	451,272
End of financial year	2,979,983	6,969,710	122,780	6,307,483	7,401,886	23,781,842

The accompanying notes form an integral part of these financial statements.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

For the financial year ended 31 March 2018

	Note	2018 \$	2017 \$
Cash flows from operating activities			
Deficit before grants		(35,411,276)	(32,332,298)
Adjustments for:			
- Depreciation		3,774,877	4,136,730
- Loss on disposal of property, plant and equipment		6,254	4,779
- Sponsorships and donations		(999,541)	(1,119,330)
- Changes in fair value of financial asset at fair value through profit or loss		(88,803)	(156,538)
- Interest income		(266,280)	(188,810)
		<u>(32,984,769)</u>	<u>(29,655,467)</u>
Change in working capital			
- Inventories		178,577	(228,808)
- Trade and other receivables		(1,538,495)	(856,777)
- Trade and other payables		(2,056,458)	383,229
Cash used in operations		<u>(36,401,145)</u>	<u>(30,357,823)</u>
Income tax paid		(10,292)	(4)
Net cash used in operating activities		<u>(36,411,437)</u>	<u>(30,357,827)</u>
Cash flows from investing activities			
Purchases of property, plant and equipment		(1,279,179)	(683,764)
Purchase of held-to-maturity financial assets		-	-
Proceeds upon maturity of held-to-maturity financial assets		1,002,500	-
Interest received		266,280	188,810
Net cash used in investing activities		<u>(10,399)</u>	<u>(494,954)</u>
Cash flows from financing activities			
Government grants received		33,326,731	33,066,028
Sponsorship received		988,874	2,307,185
Other government grants received		6,399,962	1,976,367
Excess other government grants refunded		(160,103)	(1,162,513)
Excess sponsorship refunded		(193,005)	-
Issuance of share capital		989,620	804,634
Dividends paid		(451,000)	-
Net cash from financing activities		<u>40,901,079</u>	<u>36,991,701</u>
Net increase in cash and cash equivalents		4,479,243	6,138,920
Cash and cash equivalents at beginning of financial year		23,145,695	17,006,775
Cash and cash equivalents at end of financial year	10	<u>27,624,938</u>	<u>23,145,695</u>

The accompanying notes form an integral part of these financial statements.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

The financial statements were authorized for issue by members of the Board on 4 June 2018.

1. General information

Science Centre Board (the "Board") is a Statutory Board incorporated under the Science Centre Act (Cap. 286) under the purview of the Ministry of Education ("Government" or "MOE"). The registered office and principal place of business of the Board is 15 Science Centre Road, Singapore 609081.

The principal activities of the Board are to:

- (a) Promote interest, learning and creativity in science and technology through imaginative and enjoyable experience and contribute to the nation's development of its human resource;
- (b) Conduct supplementary science classes, lectures, demonstrations and workshops to complement the school science syllabi;
- (c) Produce and publish scientific literature in the form of magazines and guidebooks;
- (d) Organise activities and programmes for targeted and general audiences so as to bring science closer to the people; and
- (e) Screen planetarium programmes and OMNIMAX films to students and the general public, using state-of-the-art audio-visual projection systems.

The principal activities of the subsidiaries are described in Note 15 to the financial statements.

2. Significant accounting policies

2.1 Basis of preparation

The financial statements have been prepared in accordance with Singapore Statutory Board Financial Reporting Standards ("SB-FRS"). The financial statements have been prepared under the historical cost convention, except as disclosed in the accounting policies below.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.1 Basis of preparation (continued)

The preparation of financial statements in conformity with SB-FRS requires management to exercise its judgement in the process of applying the Group's accounting policies. It also requires the use of certain critical accounting estimates and assumptions. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in Note 3.

Interpretations and amendments to published standards effective for the financial year ended 31 March 2018

On 1 April 2017, the Group adopted the new or amended SB-FRS and Interpretations to SB-FRS ("INT SB-FRS") that are mandatory for application from that date.

The adoption of these new or amended SB-FRS and INT SB-FRS did not result in substantial changes to the Group's accounting policies and had no material effect on the amounts reported for the current or prior financial years.

2.2 Subsidiaries

Consolidation

Subsidiaries are entities over which the Group has power to govern the financial and operating policies so as to obtain benefits from its activities, generally accompanied by a shareholding giving rise to a majority of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Group controls another entity. Subsidiaries are consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date on which control ceases.

In preparing the consolidated financial statements, transactions, balances and unrealised gains on transactions between group entities are eliminated. Unrealised losses are also eliminated but are considered an impairment indicator of the asset transferred.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.3 Joint operation

A joint operation is an arrangement in which the Group has joint control whereby the Group has rights to the assets, and obligations for the liabilities, relating to an arrangement. The Group accounts for each of its assets, liabilities and transactions, including its share of those held or incurred jointly, in relation to the joint operation.

2.4 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

(a) Admission fees

Admission fees are recognised upon the sale of admission tickets to visitors and members. Where such tickets are sold via agents, revenue is recognised at the point of sale unless the difference from recognising revenue over the validity period of the tickets is expected to be material, in which case, an adjustment is made to recognise revenue over the validity period of the tickets.

(b) Proceeds from special projects

Proceeds from special projects are income from the organisation of temporary exhibitions. Income from such projects is recognised upon the sale of tickets to visitors.

(c) Fees from courses and programmes

Fees from courses and programmes are recognised over the duration of the courses and programmes.

(d) Collections from exhibits and events

Collections from exhibits and events comprise mainly of collections from rental of travelling exhibitions and events and are recognised on a straight-line basis over the rental period.

(e) Sales of merchandise and publications

Sales of merchandise and publications are recognised at the point of sales of the merchandise and publications.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.4 Revenue recognition (continued)

(f) Service income

Service income from provision of services for set up of travelling exhibitions and organisation of corporate events are recognised when services have been rendered.

(g) Photo-taking

Income from photo-taking is recognised upon the sale of photos to visitors and members.

(h) Donations and sponsorships

Donations and sponsorships are received or receivables to meet approved expenditure for specific projects or purposes. Donations and sponsorships are recognised in profit or loss as income in the financial year when the expenditure for the specified projects or purposes is incurred. The amount that is not utilised for the specific projects or purposes is included in the sponsorship received in advance account.

(i) Rental income

Rental income from operating leases (net of any incentives given to the lessees) is recognised on a straight-line basis over the lease term.

(j) Interest income

Interest income is recognised using the effective interest method.

(k) Management fee

Management fee for the provision of services to government agencies is recognised over the period the services are rendered.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.5 Government grants

Grants from the Ministry of Education are recognised as a receivable at their fair value when there is reasonable assurance that the grants will be received and the Group will comply with all the attached conditions.

Government grants are recognised as income over the periods necessary to match them with the related costs which they are intended to reimburse, on a systematic basis. Government grants that are receivable as reimbursement for expenses already incurred are recognised in profit or loss in the period in which they become receivable.

2.6 Deferred capital grants

Government grants and contributions from other government organisations utilised for the purchase or construction of depreciable assets are recorded in the deferred capital grants account (shown as liability on the balance sheet).

Government grants whose primary condition is that the Group should purchase, construct or otherwise acquire non-current assets are recognised as deferred capital grants in the balance sheet and transferred to profit or loss over the useful lives of the related assets.

On the disposal of property, plant and equipment, the balance of the related grants is recognised in profit or loss to match the net book value of property, plant and equipment disposed.

2.7 Employee compensation

(a) *Defined contribution plans*

Defined contribution plans are post-employment benefit plans under which the Group pays fixed contributions into separate entities such as the Central Provident Fund on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid.

(b) *Employee leave entitlement*

Employee entitlements to annual leave are recognised when they accrue to employees. A provision is made for the estimated liability for annual leave as a result of services rendered by employees up to the balance sheet date.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.7 Employee compensation (continued)

(c) Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

2.8 Sponsorship Fund

The Sponsorship Fund is set up to account for contributions received from private organisations and individuals for specified purposes. The Sponsorship Fund has been conferred the Institute of Public Character status under Section 37(2)(c) of the Charities Act since 1 April 2008. The income from the Sponsorship Fund will be used to further the objectives of the Sponsorship Fund. The principal sums of the Sponsorship Fund are presented separately in the balance sheet. The Sponsorship Fund is classified as a restricted fund in accordance with SB-FRS Guidance Note 3.

2.9 Endowment Fund

The Endowment Fund is set up to account for contributions received from private organisations, individuals and other government agencies for specified purposes. The Endowment Fund was conferred the Institute of Public Character status under Section 37(2)(c) of the Charities Act from 1 April 2008 to 31 March 2013. The income from the Endowment Fund will be used to further the objectives of the Science Centre Board and specific capacity training for staffs. The principal sums of the Endowment Fund are presented separately in the balance sheet. The Endowment Fund is classified as a restricted fund in accordance with SB-FRS Guidance Note 3.

2.10 Omni-Theatre Development Fund

The Omni-Theatre Development Fund was set up to account for contributions received from private organisations and individuals. The principal sums of the Omni-Theatre Development Fund, consisting of donations and sponsorships received, are kept intact. The Omni-Theatre Development fund is classified under general funds in accordance with SB-FRS Guidance Note 3.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.11 Finance costs

Finance expenses comprise interest expense on borrowings that are recognised in profit or loss. Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognised in profit or loss using the effective interest method.

2.12 Income taxes

Current income tax for current and prior periods is recognised at the amount expected to be paid to or recovered from the tax authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date.

Deferred income tax is recognised for all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profit or loss at the time of the transaction.

A deferred income tax liability is recognised on temporary differences arising on investments in subsidiaries, except where the Group is able to control the timing of the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.

A deferred income tax asset is recognised to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilised.

Deferred income tax is measured:

- (i) at the tax rates that are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date; and
- (ii) based on the tax consequence that will follow from the manner in which the Group expects, at the balance sheet date, to recover or settle the carrying amounts of its assets and liabilities.

Current and deferred income taxes are recognised as income or expense in profit or loss.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.13 Inventories

Inventories are carried at the lower of cost and net realisable value. Cost is determined on a weighted average basis. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

2.14 Property, plant and equipment

(a) *Measurement*

Property, plant and equipment are initially recognised at cost and subsequently carried at cost less accumulated depreciation and accumulated impairment losses.

(b) *Component of costs*

The cost of an item of property, plant and equipment initially recognised includes its purchase price, capitalised borrowing cost and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Assets under construction are stated at cost, and comprise construction costs and development costs. Construction costs are recorded based on contract progress payments for certified works and services. Development costs include manpower costs and other construction overheads.

(c) *Depreciation*

Depreciation is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives as follows:

	<u>Useful lives</u>
Leasehold land	Over lease period of 99 years
Buildings	20 to 50 years
Leasehold improvements	5 years
Furniture and office equipment	3 to 5 years
Motor vehicles	10 years
OMNIMAX films	2 years

No depreciation is provided on assets under construction.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.14 Property, plant and equipment (continued)

(c) *Depreciation (continued)*

The residual values, estimated useful lives and depreciation method of property, plant and equipment are reviewed, and adjusted as appropriate, at each balance sheet date. The effects of any revision are recognised in profit or loss when the changes arise.

The following items are written off in the year of construction or purchase:

- Exhibits
- Films (other than OMNIMAX)
- Cost of publications and souvenirs
- Property, plant and equipment costing below \$2,000 each

(d) *Subsequent expenditure*

Subsequent expenditure relating to property, plant and equipment that has already been recognised is added to the carrying amount of the asset only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repair and maintenance expenses are recognised in profit or loss when incurred.

(e) *Disposal*

On disposal of an item of property, plant and equipment, the difference between the disposal proceeds and its carrying amount is recognised in profit or loss within "Other losses/(gains) – net".

2.15 Investments in subsidiaries

Investments in subsidiaries are carried at cost less accumulated impairment losses in the Board's balance sheet. On disposal of investments in subsidiaries, the difference between disposal proceeds and the carrying amounts of the investments are recognised in profit or loss.

2.16 Impairment of non-financial assets

Property, plant and equipment
Investments in subsidiaries

Property, plant and equipment and investments in subsidiaries are tested for impairment whenever there is any objective evidence or indication that these assets may be impaired.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.16 Impairment of non-financial assets (continued)

For the purpose of impairment testing of these assets, the recoverable amount (i.e. the higher of the fair value less cost to sell and value-in-use) is determined on an individual asset basis unless the asset does not generate cash inflows that are largely independent of those from other assets. If this is the case, recoverable amount is determined for the cash-generating unit ("CGU") to which the asset belongs.

If the recoverable amount of the asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. The difference between the carrying amount and recoverable amount is recognised as an impairment loss in profit or loss.

An impairment loss for an asset is reversed if, and only if, there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. The carrying amount of this asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortisation or depreciation) had no impairment loss been recognised for the asset in prior years. A reversal of impairment loss for an asset is recognised in profit or loss.

2.17 Financial assets

(a) *Classification*

The Group classifies its financial assets in the following categories: loans and receivables, fair value through profit or loss, and held-to-maturity. The classification depends on the nature of the asset and the purpose for which the assets were acquired. Management determines the classification of its financial assets at initial recognition and in the case of assets classified as held-to-maturity, re-evaluates this designation at each balance sheet date.

(i) *Loans and receivables*

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are presented as current assets, except for those expected to be realised later than 12 months after the balance sheet date which are presented as non-current assets. Loans and receivables are presented as "trade and other receivables" (Note 11) and "cash and cash equivalents" (Note 10) on the balance sheet.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.17 Financial assets (continued)

(a) *Classification (continued)*

(ii) *Financial assets at fair value through profit or loss*

This category has two sub-categories: financial assets held for trading, and those designated at fair value through profit or loss at inception. A financial asset is classified as held for trading if it is acquired principally for the purpose of selling in the short term. Financial assets designated as at fair value through profit or loss at inception are those that are managed and their performances are evaluated on a fair value basis, in accordance with a documented investment strategy.

Assets in this category are classified as current assets if they are either held for trading or are expected to be realised within 12 months after the balance sheet date.

(iii) *Held-to-maturity financial assets*

Held-to-maturity financial assets are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Group's management has the positive intention and ability to hold to maturity. If the Group were to sell other than an insignificant amount of held-to-maturity financial assets, the whole category would be tainted and reclassified as available-for-sale. They are presented as non-current assets, except for those maturing within 12 months after the balance sheet date which are presented as current assets.

(b) *Recognition and derecognition*

The Group initially recognises loans and receivables and deposits on the date that they are originated. All other financial assets (including assets designated at fair value through profit or loss) are recognised initially on the trade date, which is the date that the Group becomes a party to the contractual provisions of the instrument.

Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all risks and rewards of ownership. On disposal of a financial asset, the difference between the carrying amount and the sale proceeds is recognised in profit or loss.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.17 Financial assets (continued)

(c) *Initial measurement*

Financial assets are initially recognised at fair value plus transaction costs, except for financial assets at fair value through profit or loss, which are recognised at fair value. Transaction costs for financial assets at fair value through profit or loss are recognised immediately as expenses.

(d) *Subsequent measurement*

Financial assets, at fair value through profit or loss are subsequently carried at fair value. Loans and receivables are subsequently carried at amortised cost using the effective interest method.

Changes in the fair value of financial asset at fair value through profit or loss are recognised in income or expenditure within "other gains/(losses) – net" when the changes arise.

(e) *Impairment*

The Group assesses at each balance sheet date whether there is objective evidence that a financial asset or a group of financial assets is impaired and recognises an allowance for impairment when such evidence exists.

Loans and receivables/Held-to-maturity financial assets

Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy and default or significant delay in payments are objective evidence that these financial assets are impaired.

The carrying amount of these assets is reduced through the use of an impairment allowance account which is calculated as the difference between the carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. When the asset becomes uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are recognised against the same line item in profit or loss.

The impairment allowance is reduced through profit or loss in a subsequent period when the amount of impairment loss decreases and the related decrease can be objectively measured. The carrying amount of the asset previously impaired is increased to the extent that the new carrying amount does not exceed the amortised cost had no impairment been recognised in prior periods.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.18 Trade and other payables

Trade and other payables represent liabilities for goods and services provided to the Group prior to the end of financial year which are unpaid. They are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

Trade and other payables are initially recognised at fair value, and subsequently carried at amortised cost using the effective interest method.

2.19 Fair value estimation of financial assets and liabilities

The fair values of financial instruments that are not traded in an active market are determined by using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on market conditions existing at each balance sheet date. Where appropriate, quoted market prices or dealer quotes for similar instruments are used.

The fair values of financial liabilities carried at amortised cost are estimated by discounting the future contractual cash flows at the current market interest rates that are available to the Group for similar financial liabilities.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- (i) quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);
- (ii) inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2); and
- (iii) inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level 3).

2.20 Cash and cash equivalents

The Board is required to participate in the Centralised Liquidity Management Framework ("CLM") in accordance with the Accountant-General's Circular No.4/2009 dated 2 November 2009. All selected bank accounts of the Board maintained with selected banks are linked up with the Accountant-General's Department's ("AGD") bank accounts for available excess cash to be automatically aggregated for central management on a daily basis. The deposits held with AGD are short-term highly liquid investments that are readily convertible to known amounts of cash and are classified in cash and cash equivalents as "Deposits held with AGD".

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.20 Cash and cash equivalents (continued)

Cash at bank and on hand represents funds that are derived from non-government sources/entities, which are not required to be included in the CLM.

For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents include cash on hand and at bank, deposits held with AGD and deposits with financial institutions which are subject to an insignificant risk of change in value. Bank deposits with maturity over three months are excluded in the statement of cash flows.

2.21 Leases

(a) *When the Group is the lessee:*

The Group and the Board lease land and office equipment under operating leases from non-related parties.

Lessee - Operating leases

Leases of land where substantially all risks and rewards incidental to ownership are retained by the lessors are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessors) are recognised in profit or loss on a straight-line basis over the period of the lease.

Contingent rents are recognised as an expense in profit or loss when incurred.

(b) *When the Group is the lessor:*

The Group and the Board lease retail space under operating leases to non-related parties.

Lessor - Operating leases

Leases of retail space where the Group retains substantially all risks and rewards incidental to ownership are classified as operating leases. Rental income from operating leases (net of any incentives given to the lessees) is recognised in profit or loss on a straight-line basis over the lease term.

Initial direct costs incurred by the Group in negotiating and arranging operating leases are added to the carrying amount of the leased assets and recognised as an expense in profit or loss over the lease term on the same basis as the lease income.

Contingent rents are recognised as income in profit or loss when earned.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

2. Significant accounting policies (continued)

2.22 Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is more likely than not that an outflow of resources will be required to settle the obligation and the amount has been reliably estimated.

2.23 Currency translation

(a) *Functional and presentation currency*

Items included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment in which the entity operates ("functional currency"). The financial statements are presented in Singapore Dollars, which is the functional currency of the Board.

(b) *Transactions and balances*

Transactions in a currency other than functional currency ("foreign currency") are translated into functional currency using the exchange rates at the dates of the transactions. Currency translation differences resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at the closing rates at the balance sheet date are recognised in profit or loss.

Foreign exchange gains and losses impacting profit or loss are presented in the income statement within "other (losses)/gains – net".

2.24 Dividends

Dividends are recognised when the dividends are approved for payment to the Ministry of Finance under the Capital Management Framework - Finance Circular Minute No. M26/2008.

2.25 Share capital

Ordinary shares to the Minister for Finance are classified as equity.

2.26 Capital account

The Capital account represents the grant given by the MOE to contribute towards the repayment of the outstanding accumulated interest on a Government loan taken.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

3. Critical accounting estimates, assumptions and judgements

Estimates, assumptions and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

3.1 Critical accounting estimates and assumptions

Depreciation of property, plant and equipment

Property, plant and equipment are depreciated on a straight-line basis over the estimated useful lives, after taking into account the estimated residual value. The Group reviews the estimated useful lives of the assets regularly in order to determine the amount of depreciation expense to be recorded during any reporting period. The useful lives are based on the Group's historical experience with similar assets and taking into account anticipated technological changes. Depreciation expense for future periods is adjusted if there are significant changes from previous estimates.

3.2 Critical judgements in applying the entity's accounting policies

Held-to-maturity financial assets

The Endowment Fund follows the guidance of SB-FRS 39 on classifying non-derivative financial assets with fixed or determinable payments and fixed maturity as held-to-maturity financial assets. This classification requires significant judgement. In making this judgement, the Endowment Fund evaluates its intention and ability to hold such investments to maturity. If the Endowment Fund fails to hold these investments to maturity other than for the specific circumstances, for example, selling an insignificant amount close to maturity, it will be required to reclassify the entire class as available-for-sale. The investment would therefore be measured at fair value and no longer at amortised cost.

4. Other income

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Donations and sponsorship	999,541	1,119,330	999,541	1,119,330
Rental income	934,246	964,491	889,246	866,435
Interest income	266,280	188,810	266,280	188,810
Management fee	776,500	671,293	872,960	769,053
Others	153,717	129,911	105,836	87,041
	<u>3,130,284</u>	<u>3,073,835</u>	<u>3,133,863</u>	<u>3,030,669</u>

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2017

5. Other gains – net

	<u>Group and Board</u>	
	2018	2017
	\$	\$
Fair value changes on financial asset at fair value through profit or loss	88,803	156,538
Net currency translation losses	(488)	(69)
	<u>88,315</u>	<u>156,469</u>

6. Employee compensation

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Wages and salaries	17,694,090	18,320,929	16,492,577	17,305,126
Employer's contribution to Central Provident Fund	2,934,489	2,971,367	2,787,815	2,842,461
Other staff benefits	316,555	359,091	310,898	354,857
	<u>20,945,134</u>	<u>21,651,387</u>	<u>19,591,290</u>	<u>20,502,444</u>

7. Other expenditure

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Professional, consultancy and other fees				
- subsidiaries	-	-	625,600	234,500
- non-related parties	863,612	846,566	763,910	724,869
Cost of merchandise and publications	667,536	545,589	460,889	314,248
Printing, stationery and office supplies	146,359	167,579	133,670	146,886
Rental of equipment and venue and lease fees of films	455,653	317,746	181,183	132,811
Postage, telephone and courier charges	89,991	86,502	69,483	75,161
Loss on disposal of property, plant and equipment	6,254	4,779	6,254	4,779
Transport and travelling expenses	424,251	731,851	386,385	705,290
Refreshment and entertainment expenses	177,258	148,608	176,530	149,605
Property tax	119,903	121,304	119,903	121,304
GST input tax (non-claimable)	1,140,685	963,989	1,140,685	963,989
Royalties	36,483	203,059	36,483	203,059
Others	243,360	269,886	140,965	71,545
	<u>4,371,345</u>	<u>4,407,458</u>	<u>4,241,940</u>	<u>3,848,046</u>

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

8. Finance expenses

	Group and Board	
	2018	2017
	\$	\$
Interest expenses – others	1,880	-
Interest expenses – borrowing	-	586
	1,880	586

9. Income taxes

(a) Income tax expense

	Group	
	2018	2017
	\$	\$
Tax expense attributable to (deficit)/surplus is made up of:		
- Current income tax	-	7,541
- Deferred income tax (Note 20)	15,288	(3,824)
	15,288	3,717
Under/(over) provision in preceding financial years		
- Current income tax	2,751	(616)
- Deferred income tax (Note 20)	(22,513)	-
	(19,762)	(616)
Income tax (credit)/expense	(4,474)	3,101

The tax expense on the Group's results differs from the theoretical amount that would arise using the Singapore standard rate of income tax as follows:

	Group	
	2018	2017
	\$	\$
Surplus before tax	1,127,199	131,691
Tax credit calculated at a tax rate of 17% (2017: 17%)	191,624	22,387
Effects of:		
- Surplus of the Board exempted from tax	(214,609)	(76,716)
- Statutory stepped income exemption	-	(23,472)
- Expenses not deductible for tax purposes	14,294	44,835
- Income not subject to tax	(7,486)	(6,509)
- Deferred tax assets not recognised	32,953	40,771
- Overprovision in preceding financial years	(19,762)	(616)
- Others	(1,488)	2,421
Income tax (credit)/expense	(4,474)	3,101

As a statutory board, the Board is exempted from income tax.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

9. Income taxes (continued)

(a) Income tax expense (continued)

Deferred income tax assets are recognised for tax losses and capital allowances carried forward only to the extent that realisation of the related tax benefits through the future taxable profits is probable. Deferred tax assets have not been recognised in respect of tax losses and deductible temporary difference amounting to approximately \$816,859 (2017: \$750,724) and \$127,706 (2017: \$Nil), respectively, because it is not probable that future taxable profit will be available against which the Group can use the benefits therefrom.

(b) Movements in current income tax liabilities

	<u>Group</u>	
	2018	2017
	\$	\$
Beginning of financial year	7,541	620
Income tax paid	(10,292)	(472)
Provision for the financial year	-	7,541
Over/(under) provision in preceding financial years	2,751	(148)
End of financial year	<u>-</u>	<u>7,541</u>

10. Cash and cash equivalents

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Deposits held with AGD	23,071,543	21,241,056	23,071,543	21,241,056
Cash at bank and on hand	4,553,395	1,904,639	3,875,879	1,174,063
Short term bank deposits	1,000,000	1,000,000	1,000,000	1,000,000
	<u>28,624,938</u>	<u>24,145,695</u>	<u>27,947,422</u>	<u>23,415,119</u>

For the purpose of presenting the consolidated cash flow statement, the consolidated cash and cash equivalents comprise the following:

	2018	2017
	\$	\$
Cash and cash equivalents (as above)	28,624,938	24,145,695
Less: Short term bank deposits with maturity of more than 3 months	(1,000,000)	(1,000,000)
Cash and cash equivalents per consolidated cash flow statement	<u>27,624,938</u>	<u>23,145,695</u>

Short term bank deposits at the balance sheet date bear average effective interest rate of 1.22% (2017: 1.18% to 1.7%) and have a tenure of 6 months (2017: 6 months to 12 months).

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

10. Cash and cash equivalents (continued)

Deposits held with the Accountant-General's Department ("AGD") earn interest based on fixed deposit rates determined by financial institutions with which AGD deposits the monies.

11. Trade and other receivables

	Group		Board	
	2018	2017	2018	2017
	\$	\$	\$	\$
Trade receivables				
- subsidiaries	-	-	135,722	257,705
- external parties	2,432,085	1,295,143	2,378,143	1,125,156
Trade receivables - net	2,432,085	1,295,143	2,513,865	1,382,861
Non-trade receivables from				
subsidiary	-	-	3,881	3,881
Sponsorship receivables	96,740	183,895	96,740	183,895
Other government grants receivable (see below)	92,121	1,912,158	92,121	1,912,158
Government grant receivable	329,338	-	329,338	-
Deposits	23,698	15,555	-	1,000
Prepayments	163,692	219,649	141,819	190,563
Other receivables	286,395	47,718	274,519	41,222
	3,424,069	3,674,118	3,452,283	3,175,580

Other government grants refer to grants received from Ministries, Organs of States and other Statutory Boards.

Other government grants

	Group		Board	
	2018	2017	2018	2017
	\$	\$	\$	\$
Other government grants receivable	92,121	1,912,158	92,121	1,912,158
Other government grants received in advance	(1,990,216)	(725,188)	(1,990,216)	(725,188)
	(1,898,095)	1,186,970	(1,898,095)	1,186,970

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

11. Trade and other receivables (continued)

Other government grants (continued)

Movement in other government grants receivable/(received in advance) is as follows:

Group

	<u>Receivable</u>		<u>Received in advance</u>		<u>Total</u>	
	2018	2017	2018	2017	2018	2017
	\$	\$	\$	\$	\$	\$
Beginning of financial year	1,912,158	2,550,272	(725,188)	(1,669,829)	1,186,970	880,443
Less: Grants received during the year	(1,905,457)	(965,100)	(4,494,505)	(1,011,267)	(6,399,962)	(1,976,367)
Add: Amount recognised in profit or loss	85,420	323,864	3,014,038	743,691	3,099,458	1,067,555
Add: Amount transferred to deferred capital grants (Note 21)	-	2,969	6,376	134,873	6,376	137,842
Less: Amount returned	-	153	160,103	1,162,360	160,103	1,162,513
Add/less: Others	-	-	48,960	(85,016)	48,960	(85,016)
End of financial year	<u>92,121</u>	<u>1,912,158</u>	<u>(1,990,216)</u>	<u>(725,188)</u>	<u>(1,898,095)</u>	<u>1,186,970</u>

Board

	<u>Receivable</u>		<u>Received in advance</u>		<u>Total</u>	
	2018	2017	2018	2017	2018	2017
	\$	\$	\$	\$	\$	\$
Beginning of financial year	1,912,158	2,447,879	(725,188)	(1,669,829)	1,186,970	778,050
Less: Grants received during the year	(1,905,457)	(862,707)	(4,471,287)	(946,969)	(6,376,744)	(1,809,676)
Add: Amount recognised in profit or loss	85,420	323,864	2,990,820	731,743	3,076,240	1,055,607
Add: Amount transferred to deferred capital grants (Note 21)	-	2,969	6,376	82,523	6,376	85,492
Less: Amount returned	-	153	160,103	1,162,360	160,103	1,162,513
Add/less: Others	-	-	48,960	(85,016)	48,960	(85,016)
End of financial year	<u>92,121</u>	<u>1,912,158</u>	<u>(1,990,216)</u>	<u>(725,188)</u>	<u>(1,898,095)</u>	<u>1,186,970</u>

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

12. Financial asset at fair value through profit or loss

	<u>Group and Board</u>	
	<u>2018</u>	<u>2017</u>
	\$	\$
Fullerton Conservative Balanced Fund ("Fullerton Fund")	<u>4,317,805</u>	<u>4,229,002</u>

The Fullerton Fund has a nominal value amounting to \$3,900,000 (2017: \$3,900,000).

The fair value of the Fullerton Fund is provided by the Fund Manager and determined based on estimated valuations derived from market quotations and are within level 2 of the fair value hierarchy.

Changes in the fair value of the financial asset at fair value through profit or loss amounting to \$88,803 (2017: \$156,496) have been included in the statement of comprehensive income for the year.

13. Held-to-maturity financial assets

	<u>Group and Board</u>	
	<u>2018</u>	<u>2017</u>
	\$	\$
Quoted corporate bonds, at amortised cost	<u>1,018,000</u>	<u>2,020,500</u>
Classified as:		
- Current		- 1,002,500
- Non-current	<u>1,018,000</u>	<u>1,018,000</u>
	<u>1,018,000</u>	<u>2,020,500</u>

The quoted corporate bonds have nominal value amounting to \$1,000,000 (2017: \$2,000,000), with coupon rates of 2.58% (2016: 1.23% to 2.58%) per annum and matures on 24 September 2020 (2017: 30 January 2018 to 24 September 2020). The average effective interest rate of the quoted corporate bonds is 2.17% (2017: 1.18% to 2.17%). All the bonds carry a fixed coupon rate.

The fair values of the bonds are provided by banks employing generally market accepted valuation parameters and techniques. The quoted corporate bonds have fair values amounting to \$999,000 (2017: \$1,993,900) and are within level 2 of the fair value hierarchy.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

14. Inventories

	Group		Board	
	2018	2017	2018	2017
	\$	\$	\$	\$
Finished goods	<u>397,173</u>	<u>575,750</u>	<u>168,579</u>	<u>205,302</u>

Inventories comprised finished goods held at cost for resale purposes.

The cost of inventories recognised as an expense and included in "Other expenditure" amounts to \$667,536 (2017: \$545,589) for the Group and \$460,805 (2017: \$292,788) for the Board.

At 31 March 2018, the write-down of inventories to net realisable value by the Group and Board amounted to \$40,270 (2017: \$68,572) and \$2,010 (2017: \$2,143) respectively.

15. Investments in subsidiaries

	Board	
	2018	2017
	\$	\$
Unquoted equity investments at cost	<u>1,760,002</u>	<u>1,760,002</u>

Details of the subsidiaries are as follows:

Name of companies	Principal activities	Country of business/ incorporation	Equity holding	
			2018	2017
			%	%
Singapore Science Centre Global ^(a)	Investment holding, marketing and promotional activities for related entities and participation in joint ventures and collaboration projects, with educational and entertainment elements, on an academic and commercial basis.	Singapore	100	100
Snow Venture Pte Ltd ^(a)	Proprietor and operator of entertainment centre	Singapore	100	100

(a) Audited by KPMG LLP, Singapore

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2017

16. Property, plant and equipment

Group

	Leasehold land \$	Buildings \$	Leasehold improvements \$	Furniture and office equipment \$	Motor vehicles \$	OMNIMAX films \$	Assets under construction \$	Total \$
2018								
<u>Cost</u>								
Beginning of financial year	3,754,976	42,740,996	21,869,918	17,822,049	268,315	602,594	112,655	87,171,503
Additions	-	-	945,160	331,359	-	-	2,660	1,279,179
Disposals	-	-	-	(1,523,284)	-	-	-	(1,523,284)
Reclassifications	-	-	-	112,655	-	-	(112,655)	-
End of financial year	3,754,976	42,740,996	22,815,078	16,742,779	268,315	602,594	2,660	86,927,398
<u>Accumulated depreciation</u>								
Beginning of financial year	1,284,140	26,556,594	18,940,723	14,398,646	258,107	602,594	-	62,040,804
Depreciation charge	36,376	1,085,297	1,275,019	1,374,924	3,261	-	-	3,774,877
Disposals	-	-	-	(1,517,030)	-	-	-	(1,517,030)
End of financial year	1,320,516	27,641,891	20,215,742	14,256,540	261,368	602,594	-	64,298,651
Net book value								
End of financial year	2,434,460	15,099,105	2,599,336	2,486,239	6,947	-	2,660	22,628,747

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

16. Property, plant and equipment (continued)

Group (continued)

	Leasehold land \$	Buildings \$	Leasehold improvements \$	Furniture and office equipment \$	Motor vehicles \$	OMNIMAX films \$	Assets under construction \$	Total \$
2017								
Cost								
Beginning of financial year	3,754,976	42,740,996	21,752,725	17,521,906	268,315	602,594	131,305	86,772,817
Additions	-	-	117,193	505,490	-	-	61,081	683,764
Disposals	-	-	-	(285,078)	-	-	-	(285,078)
Reclassifications	-	-	-	79,731	-	-	(79,731)	-
End of financial year	3,754,976	42,740,996	21,869,918	17,822,049	268,315	602,594	112,655	87,171,503
Accumulated depreciation								
Beginning of financial year	1,247,763	25,470,757	17,371,285	13,238,091	253,883	602,594	-	58,184,373
Depreciation charge	36,377	1,085,837	1,569,438	1,440,854	4,224	-	-	4,136,730
Disposals	-	-	-	(280,299)	-	-	-	(280,299)
End of financial year	1,284,140	26,556,594	18,940,723	14,398,646	258,107	602,594	-	62,040,804
Net book value								
End of financial year	2,470,836	16,184,402	2,929,195	3,423,403	10,208	-	112,655	25,130,699

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

16. Property, plant and equipment (continued)

Board

	Leasehold land \$	Buildings \$	Leasehold improvements \$	Furniture and office equipment \$	Motor vehicles \$	OMNIMAX films \$	Assets under construction \$	Total \$
2018								
<u>Cost</u>								
Beginning of financial year	3,754,976	41,478,610	20,466,578	17,250,249	268,315	602,594	112,655	83,933,977
Additions	-	-	910,265	203,100	-	-	2,660	1,116,025
Disposals	-	-	-	(1,523,284)	-	-	-	(1,523,284)
Transfers	-	-	-	112,655	-	-	(112,655)	-
End of financial year	3,754,976	41,478,610	21,376,843	16,042,720	268,315	602,594	2,660	83,526,718
<u>Accumulated depreciation</u>								
Beginning of financial year	1,284,140	25,353,269	18,337,669	14,275,602	258,107	602,594	-	60,111,381
Depreciation charge	36,376	1,060,135	1,015,833	1,240,028	3,261	-	-	3,355,633
Disposals	-	-	-	(1,517,030)	-	-	-	(1,517,030)
End of financial year	1,320,516	26,413,404	19,353,502	13,998,600	261,368	602,594	-	61,949,984
Net book value								
End of financial year	2,434,460	15,065,206	2,023,341	2,044,120	6,947	-	2,660	21,576,734

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

16. Property, plant and equipment (continued)

Board (continued)

2017	Leasehold land \$	Buildings \$	Leasehold improvements \$	Furniture and office equipment \$	Motor vehicles \$	OMNIMAX films \$	Assets under construction \$	Total \$
Cost								
Beginning of financial year	3,754,976	41,478,610	20,349,385	16,986,459	268,315	602,594	131,305	83,571,644
Additions	-	-	117,193	466,437	-	-	61,081	644,711
Disposals	-	-	-	(282,378)	-	-	-	(282,378)
Transfers	-	-	-	79,731	-	-	(79,731)	-
End of financial year	3,754,976	41,478,610	20,466,578	17,250,249	268,315	602,594	112,655	83,933,977
Accumulated depreciation								
Beginning of financial year	1,247,763	24,293,134	17,048,084	13,244,298	253,883	602,594	-	56,689,756
Depreciation charge	36,377	1,060,135	1,289,585	1,308,903	4,224	-	-	3,699,224
Disposals	-	-	-	(277,599)	-	-	-	(277,599)
End of financial year	1,284,140	25,353,269	18,337,669	14,275,602	258,107	602,594	-	60,111,381
Net book value								
End of financial year	2,470,836	16,125,341	2,128,909	2,974,647	10,208	-	112,655	23,822,596

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2017

17. Government grants received in advance

	<u>Group and Board</u>	
	2018	2017
	\$	\$
Beginning of financial year	10,153,612	7,360,788
Add: Grants received during the year	33,326,731	33,066,028
Less: Amount transferred to deferred capital grants (Note 21)	(75,565)	(120,266)
Less: Amount recognised in profit or loss	<u>(32,200,552)</u>	<u>(30,152,938)</u>
End of financial year	<u>11,204,226</u>	<u>10,153,612</u>

18. Sponsorship received in advance

	2018	2017
	\$	\$
Beginning of financial year	888,850	506,115
Add: Sponsorship granted during the year	876,322	1,515,371
Less: Amount transferred to deferred capital grants (Note 21)	(3,475)	(13,306)
Less: Amount recognised in profit or loss	<u>(999,541)</u>	<u>(1,119,330)</u>
End of financial year	<u>762,156</u>	<u>888,850</u>

19. Trade and other payables

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Trade payables to				
- external parties	998,157	810,119	855,306	681,454
- subsidiaries	-	-	134,830	5,701
	<u>998,157</u>	810,119	<u>990,136</u>	687,155
Non-trade payables to				
- non-related parties	1,084,292	2,631,525	1,082,491	2,624,561
- other government agency	145,548	280,998	118,536	282,952
- subsidiaries	-	-	92,623	11,220
Other payables	60,977	-	-	-
Deposits received	190,863	195,598	206,253	213,106
Deferred income	387,471	589,557	227,574	243,901
Other accruals for operating expenses	<u>2,073,749</u>	2,515,125	<u>1,956,337</u>	2,407,783
	<u>4,941,057</u>	7,022,922	<u>4,673,950</u>	6,470,678

Non-trade payables to subsidiaries are unsecured, interest-free and repayable on demand.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

20. Deferred income taxes

	Group	
	2018	2017
	\$	\$
Beginning of financial year	55,478	59,302
Tax charged to profit or loss (Note 9(a))	<u>(7,225)</u>	<u>(3,824)</u>
End of financial year	<u>48,253</u>	<u>55,478</u>

The movement in deferred income tax liabilities during the financial year is as follows:

Deferred income tax liabilities

	Accelerated tax depreciation	Total
	\$	\$
2018		
Beginning of financial year	55,478	55,478
Tax charged to profit or loss	<u>(7,225)</u>	<u>(7,225)</u>
End of financial year	<u>48,253</u>	<u>48,253</u>
2017		
Beginning of financial year	59,302	59,302
Tax charged to profit or loss	<u>(3,824)</u>	<u>(3,824)</u>
End of financial year	<u>55,478</u>	<u>55,478</u>

21. Deferred capital grants

	Government		Others		Total	
	2018	2017	2018	2017	2018	2017
	\$	\$	\$	\$	\$	\$
Beginning of financial year	16,918,592	17,855,653	351,379	386,400	17,269,971	18,242,053
Add: Transferred from						
- government grants (Note 17)	75,565	120,266	-	-	75,565	120,266
- other government grants (Note 11)	-	-	6,376	137,842	6,376	137,842
- sponsorship (Note 18)	-	-	3,475	13,306	3,475	13,306
Less: Amount recognised in profit or loss	<u>(1,086,019)</u>	<u>(1,057,327)</u>	<u>(152,446)</u>	<u>(186,169)</u>	<u>(1,238,465)</u>	<u>(1,243,496)</u>
End of financial year	<u>15,908,138</u>	<u>16,918,592</u>	<u>208,784</u>	<u>351,379</u>	<u>16,116,922</u>	<u>17,269,971</u>
Total deferred capital grants received (included in government grants received) since inception of the Board	<u>74,501,959</u>	<u>74,426,394</u>	<u>13,828,950</u>	<u>13,819,099</u>	<u>88,330,909</u>	<u>88,245,493</u>

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2017

21. Deferred capital grants (continued)

Board

	<u>Government</u>		<u>Others</u>		<u>Total</u>	
	2018	2017	2018	2017	2018	2017
	\$	\$	\$	\$	\$	\$
Beginning of financial year	16,918,592	17,855,653	229,339	278,420	17,147,931	18,134,073
Add: Transferred from						
- government grants (Note 17)	75,565	120,266	-	-	75,565	120,266
- other government grants (Note 11)	-	-	6,376	85,492	6,376	85,492
- sponsorship (Note 18)	-	-	3,475	13,306	3,475	13,306
Less: Amount recognised in profit or loss	(1,053,489)	(1,057,327)	(152,446)	(147,879)	(1,205,935)	(1,205,206)
End of financial year	<u>15,940,668</u>	<u>16,918,592</u>	<u>86,744</u>	<u>229,339</u>	<u>16,027,412</u>	<u>17,147,931</u>
Total deferred capital grants received (included in government grants received) since inception of the Board	<u>74,501,959</u>	<u>74,426,394</u>	<u>13,635,007</u>	<u>13,625,156</u>	<u>88,136,966</u>	<u>88,051,550</u>

22. Capital account

The Board's capital account represents:

- (a) the grant of \$1,640,347 given by the MOE in the financial year 1993/94 to contribute towards the repayment of the outstanding accumulated interest on a Government loan taken in 1984 for the purchase of a piece of leasehold land for the Omni-Theatre; and
- (b) the conversion of a Government loan and the related outstanding accumulated interest amounting to \$1,339,636. The loan was utilised by the Board in 1988 to finance the building of the Omni-Theatre. The conversion of the loan and outstanding accumulated interest to capital was approved by the Ministry of Finance in the financial year ended 31 March 2001.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

23. Share capital

	<u>Group and Board</u>	
	<u>2018</u>	<u>2017</u>
	\$	\$
Beginning of financial year	6,969,710	6,165,076
Issue of new shares	989,620	804,634
End of financial year	<u>7,959,330</u>	<u>6,969,710</u>

For the year ended 31 March 2018, the Board issued 989,620 (2017: 804,634) ordinary shares for a total consideration of \$989,620 (2017: \$804,634) as part of the Capital Management Framework for Statutory Boards under Finance Circular Minute M26/2008. The shares are fully paid and are held by the Minister for Finance, a body corporate incorporated by the Minister for Finance (Incorporation) Act (Chapter 183).

The holders of these shares are entitled to receive dividends as and when declared by the Board. The shares carry neither voting rights nor par value.

24. Restricted funds

Restricted funds comprise of the Sponsorship Fund and the Endowment Fund:

Statement of Comprehensive Income - Restricted Funds

Board	<u>Sponsorship</u>	<u>Endowment</u>	<u>Total</u>
	\$	\$	\$
2018			
Other income	1,007,069	134,556	1,141,625
Expenses	(1,004,141)	(48,253)	(1,052,394)
Net surplus for the year	2,928	86,303	89,231
Accumulated surplus brought forward	77,884	7,324,002	7,401,886
Accumulated surplus carried forward	<u>80,812</u>	<u>7,410,305</u>	<u>7,491,117</u>
2017			
Other income	1,122,261	206,077	1,328,338
Expenses	(1,120,466)	(49,539)	(1,170,005)
Net surplus for the year	1,795	156,538	158,333
Accumulated surplus brought forward	76,089	7,167,464	7,243,553
Accumulated surplus carried forward	<u>77,884</u>	<u>7,324,002</u>	<u>7,401,886</u>

Sponsorship income relates to expenditure incurred which will be subsequently reimbursed by the sponsors of the events. The amount reimbursable is correspondingly recorded as sponsorship receivables under trade and other receivables (Note 11).

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES**NOTES TO THE FINANCIAL STATEMENTS***For the financial year ended 31 March 2018***24. Restricted funds (continued)****Balance Sheet - Restricted Funds**

Board	Sponsorship	Endowment	Total
	\$	\$	\$
2018			
ASSETS			
Current assets			
Cash and cash equivalents	2,155,343	2,120,592	4,275,935
Trade receivables	93,178	-	93,178
Other receivables	4,755	2,526	7,281
Sponsorship receivable (Note 11)	96,740	-	96,740
Financial asset at fair value through profit or loss (Note 12)	-	4,317,805	4,317,805
	2,350,016	6,440,923	8,790,939
Non-current assets			
Held-to-maturity financial assets (Note 13)	-	1,018,000	1,018,000
Property, plant and equipment	11,003	-	11,003
	11,003	1,018,000	1,029,003
Total assets	2,361,019	7,458,923	9,819,942
LIABILITIES			
Current liabilities			
Trade and other payables	1,507,048	48,618	1,555,666
Sponsorship received in advance (Note 18)	762,156	-	762,156
	2,269,204	48,618	2,317,822
Non-current liabilities			
Deferred capital grants	11,003	-	11,003
	11,003	-	11,003
Total liabilities	2,280,207	48,618	2,328,825
NET ASSETS	80,812	7,410,305	7,491,117

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

24. Restricted funds (continued)

Balance Sheet - Restricted Funds (continued)

Board	<u>Sponsorship</u>	<u>Endowment</u>	<u>Total</u>
	\$	\$	\$
2017			
ASSETS			
Current assets			
Cash and cash equivalents	684,439	1,119,444	1,803,883
Trade receivables	94,913	-	94,913
Other receivables	136,460	4,618	141,078
Sponsorship receivable (Note 11)	183,895	-	183,895
Held-to-maturity financial assets (Note 13)	-	1,002,500	1,002,500
Financial asset at fair value through profit or loss (Note 12)	-	4,229,002	4,229,002
	<u>1,099,707</u>	<u>6,355,564</u>	<u>7,455,271</u>
Non-current assets			
Held-to-maturity financial assets (Note 13)	-	1,018,000	1,018,000
Property, plant and equipment	12,128	-	12,128
	<u>12,128</u>	<u>1,018,000</u>	<u>1,030,128</u>
Total assets	<u>1,111,835</u>	<u>7,373,564</u>	<u>8,485,399</u>
LIABILITIES			
Current liabilities			
Trade and other payables	132,973	49,562	182,535
Sponsorship received in advance (Note 18)	888,850	-	888,850
	<u>1,021,823</u>	<u>49,562</u>	<u>1,071,385</u>
Non-current liabilities			
Deferred capital grants	12,128	-	12,128
	<u>12,128</u>	<u>-</u>	<u>12,128</u>
Total liabilities	<u>1,033,951</u>	<u>49,562</u>	<u>1,083,513</u>
NET ASSETS	<u>77,884</u>	<u>7,324,002</u>	<u>7,401,886</u>

25. Omni-Theatre Development Fund

The Omni-Theatre Development Fund was set up with contributions received from private organisations and individuals. The income of this fund is taken to the profit or loss and is used for:

- (i) replacing the various specialised and highly technical projector systems and sound equipment;
- (ii) leasing of OMNIMAX movies; and
- (iii) producing Planetarium shows.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

25. Omni-Theatre Development Fund (continued)

	<u>Group and Board</u>	
	<u>2018</u>	<u>2017</u>
	\$	\$
Beginning and end of financial year	<u>122,780</u>	<u>122,780</u>
Represented by:		
Cash at bank and on hand	<u>122,780</u>	<u>122,780</u>

26. Commitments

(a) Operating lease commitments - where the Group is a lessee

The Group and the Board lease land and office equipment from non-related parties under non-cancellable operating lease agreements. The leases have varying terms, escalation clauses and renewal rights.

The future minimum lease payables under non-cancellable operating leases contracted for at the balance sheet date but not recognised as liabilities, are as follows:

	<u>Group and Board</u>	
	<u>2018</u>	<u>2017</u>
	\$	\$
Not later than one year	3,253	3,253
Between one and five years	4,337	7,554
Later than five years	1,731	1,767
	<u>9,321</u>	<u>12,574</u>

(b) Operating lease commitments - where the Group is a lessor

The Group and the Board lease out retail space to non-related parties under non-cancellable operating leases. The lessees are required to pay either absolute fixed annual increase to the lease payments or contingent rents computed based on their sales achieved during the lease period.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

26. Commitments (continued)

(b) Operating lease commitments - where the Group is a lessor (continued)

The future minimum lease receivables under non-cancellable operating leases contracted for at the balance sheet date but not recognised as receivables, are as follows:

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Not later than one year	264,745	422,341	348,745	501,341
Between one and five years	57,735	56,810	85,735	176,810
	322,480	479,151	434,480	678,151

27. Financial risk management

Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including currency risk, price risk and interest rate risk), credit risk and liquidity risk.

The Board is responsible for setting the objectives and underlying principles of financial risk management for the Group. The Board then establishes detailed policies such as risk identification and measurement and exposure limits.

The information presented below is based on information received by the key management.

(a) Market risk

(i) *Currency risk*

The Group has no significant exposure to foreign currencies as its operations are substantially denominated in Singapore dollars, which is also its functional currency.

(ii) *Price risk*

To manage its price risk arising from these investments, the Group manages its investment portfolio in accordance with investment guidelines and limits set by the Group for the portfolio. For its equity securities designated at fair value through profit or loss, the impact of a 5% increase in the fair value of the Fund at the reporting date on net surplus would have been an increase of \$215,890 (2017: \$211,450). An equal change in the opposite direction would have decrease net surplus by \$215,890 (2017: \$211,450).

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

27. Financial risk management (continued)

(a) Market risk (continued)

(iii) *Interest rate risk*

Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The Group's exposure to cash flow interest rate risk arises from interest-bearing assets consisting mainly of cash balances and fixed deposits maintained/managed by AGD. The cash balances and fixed deposits maintained/managed by AGD under centralised liquidity management are placed with high credit quality financial institution and are expected to move in tandem with market interest rate movements. The Group is not exposed to interest rate risk arising from held-to-maturity financial assets as the bonds carry a fixed coupon rate.

As the Group does not have other significant interest-bearing assets at floating rates, the Group's income is substantially independent of changes in market interest rates. Accordingly, no sensitivity analysis is presented. Information relating to the Group's interest rate exposure are disclosed in the respective notes to the financial statements.

(b) Credit risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the Group. The major classes of financial assets of the Group are cash and cash equivalents, trade and other receivables, financial asset at fair value through profit or loss and held-to-maturity financial assets.

For trade receivables, the Group adopts the policy of dealing only with customers of appropriate credit history, and obtaining sufficient security where appropriate to mitigate credit risk. For other financial assets including deposits held with AGD, the Group adopts the policy of dealing only with high credit quality counterparties such as reputable financial institutions. Concentrations of credit risk with respect to trade receivables are limited due to the Group's large number of customers. Due to these factors, management believes that no additional credit risk beyond the amount of allowance for impairment made is inherent in the Group's trade receivables.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

27. Financial risk management (continued)

(b) Credit risk (continued)

The maximum exposure to credit risk for each class of financial instruments is the carrying amount of that class of financial instruments presented on the balance sheet. The Group does not hold any collateral in respect of their financial assets.

The age analysis of trade receivables is as follows:

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Current	1,243,760	607,869	1,310,833	698,705
Past due 0 to 2 months	1,067,452	517,302	1,088,772	514,184
Past due over 2 months	120,873	169,972	114,260	169,972
	<u>2,432,085</u>	<u>1,295,143</u>	<u>2,513,865</u>	<u>1,382,861</u>

(i) *Financial assets that are neither past due nor impaired*

Cash and cash equivalents that are neither past due nor impaired are mainly deposits with banks with high credit-ratings assigned by international credit-rating agencies. Deposits held with AGD are available for withdrawal upon request from AGD. Trade and other receivables that are neither past due nor impaired are substantially institutions and companies with a good collection track record with the Group. For financial assets, the Group adopts the policy of dealing only with high credit quality counterparties.

(ii) *Financial assets that are past due and/or impaired*

There is no other class of financial assets that is past due and/or impaired except for trade receivables. The age analysis of trade receivables past due but not impaired is set out above.

There is no allowance for doubtful debts rising from these outstanding balances. The Board believes that the past due amounts are still collectible in full, based on historical payment behaviour and analysis of debtors' credit risk.

(c) Liquidity risk

Liquidity risk is the risk that the Board will not be able to meet its financial obligations as and when they fall due. The Board's approach to maintain liquidity is to ensure sufficient funding from the government and other government agencies and maintains a level of cash and cash equivalents deemed adequate by management to finance its operations.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

27. Financial risk management (continued)

(c) Liquidity risk (continued)

The table below analyses non-derivative financial liabilities of the Group and the Board into relevant maturity groupings based on the remaining period from the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

	2018	2017
	\$	\$
Group		
Trade and other payables		
- Less than 1 year	4,553,586	6,433,365
- Between 1 and 5 years	25,407	—
	<u>4,578,993</u>	<u>6,433,365</u>
Board		
Trade and other payables		
- Less than 1 year	<u>4,446,376</u>	<u>6,226,777</u>

(d) Capital risk

The Board's objectives when managing capital are to ensure that the Board is adequately capitalised and to fulfill objectives for which monies of the Board may be applied under the Act. To achieve these objectives, the Board may secure grants from Government or other government agencies, return as capital to shareholders, issue new shares, or obtain new borrowings.

The Board is not subject to any capital requirements under the Act or any other externally imposed capital requirements, except for those mandated by the Ministry of Finance.

The Board defines capital as share capital, capital account, funds and accumulated surplus. The Board monitors its net surplus/deficits. The Board's approach to capital management remains unchanged from the previous financial year ended 31 March 2017.

(e) Fair values

Financial assets

Information on the determination of fair values of financial assets at fair value through profit or loss and held-to-maturity has been separately disclosed in Notes 12 and 13.

In 2018 and 2017, there were no transfers between the different levels of the fair value hierarchy.

Other financial assets and liabilities

The carrying values of other financial assets and liabilities with a maturity of less than one year (including trade and other receivables, cash and cash equivalents, and trade and other payables) are assumed to approximate their fair values because of the short period to maturity.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

27. Financial risk management (continued)

(f) Financial instruments by category

The aggregate carrying amount of loans and receivables and financial liabilities at amortised cost are as follows:

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Loans and receivables	31,885,315	27,600,164	31,257,886	26,400,136
Financial assets, at fair value through profit or loss	4,317,805	4,229,002	4,317,805	4,229,002
Held-to-maturity financial assets	1,018,000	2,020,500	1,018,000	2,020,500
Financial liabilities at amortised cost	(4,578,993)	(6,433,365)	(4,446,376)	(6,226,777)

28. Related party transactions

In addition to the information disclosed elsewhere in the financial statements, the following transactions took place between the Group and related parties at terms agreed between the parties:

(a) Sales of goods and/or services to government

	<u>Group</u>	
	2018	2017
	\$	\$
Admission fees received from government	30,657	21,050
Proceeds from special projects received from government	9,397	24,060
Fees from courses and programmes from government	189,396	191,164
Sales of merchandise and publications to government	3,559	3,352

(b) Donations and sponsorships

	<u>Group</u>	
	2018	2017
	\$	\$
Donations and sponsorships from other government agencies	43,771	16,521

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

28. Related party transactions (continued)

(c) Key management personnel compensation

Key management personnel compensation is as follows:

	<u>Group</u>		<u>Board</u>	
	2018	2017	2018	2017
	\$	\$	\$	\$
Wages and salaries	1,062,559	1,278,338	935,370	1,151,451
Post-employment benefits - contributions to CPF	73,113	79,701	59,720	65,654
	<u>1,135,672</u>	<u>1,358,039</u>	<u>995,090</u>	<u>1,217,105</u>

29. New or revised accounting standards and interpretations

A number of new standards, amendments to standards and interpretations are effective for annual periods beginning on or after 1 April 2018, and have not been applied in preparing these financial statements.

These new standards include, among others, SB-FRS 115 *Revenue from Contracts with Customers* and SB-FRS 109 *Financial Instruments* which are mandatory for adoption by the Group on 1 April 2018.

SB-FRS 115 Revenue from Contracts with Customers

SB-FRS 115 establishes a comprehensive framework for determining whether, how much and when revenue is recognised. It also introduces new cost guidance which requires certain costs of obtaining and fulfilling contracts to be recognised as separate assets when specific criteria are met.

The Group plans to adopt SB-FRS 115 in its financial statements for the year ending 31 March 2019, using the retrospective approach. As a result, the Group will apply all of the requirements of SB-FRS 115 retrospectively, and the comparative period presented in the 2019 financial statements will be restated.

Based on the Group's existing revenue arrangement, the Group expects its revenue stream to constitute a single performance obligation. As a result, the Group does not expect a significant impact on the timing of revenue recognition.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

29. New or revised accounting standards and interpretations (continued)

SB-FRS 109 Financial Instruments

SB-FRS 109 contains new requirements for classification and measurement of financial instruments and a new expected credit loss model for calculating impairment of financial assets.

Changes in accounting policies resulting from the adoption of SB-FRS 109 will generally be applied by the Group retrospectively, except as described below.

- The following assessments have to be made on the basis of facts and circumstances that existed at 1 April 2018:
 - The determination of the business model within which a financial assets is held.
 - The determination of whether contractual terms of a financial asset give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding.
 - The designation of an investment in equity instruments that is not held for trading as at fair value through other comprehensive income (FVOCI).
 - The designation and revocation of previous designations of certain financial assets and financial liabilities measured at fair value through profit or loss (FVTPL).

The expected impact on adoption of SB-FRS 109 is not expected to be material.

Classification and measurement: financial assets

For financial assets currently held at fair value, the Group expects to continue measuring these assets at fair value under SB-FRS 109. For financial asset that have been designated at FVTPL, the Group expects to continue measuring these assets at FVTPL.

Impairment

SB-FRS 109 replaces the current 'incurred loss model' in SB-FRS 39 with a forward-looking 'expected credit loss' (ECL) model. The new impairment model will apply to financial assets measured at amortised cost, certain loan commitments and financial guarantee contracts.

The Group plans to apply the simplified approach and record lifetime ECL on all trade receivables and any contract assets arising from the application of SB-FRS 115. The Group does not expect a significant impact from the new impairment model.

The Group is currently finalising the assessment of its expected credit losses and the quantum of the final transition adjustments may be different upon finalisation.

SCIENCE CENTRE BOARD AND ITS SUBSIDIARIES

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2018

29. New or revised accounting standards and interpretations (continued)

SB-FRS116 Leases

SB-FRS116 replaces existing lease accounting guidance. SB-FRS116 is effective for annual periods beginning on or after 1 April 2019, with early adoption permitted if SB-FRS 115 is also applied. SB-FRS116 eliminates the lessee's classification of leases as either operating leases or finance leases and introduces a single lessee accounting model. Applying the new model, a lessee is required to recognise right-of-use (ROU) assets and lease liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value.

The Group plans to adopt the standard when it becomes effective in 2019 and expects to apply the standard using the modified retrospective approach. The Group also expects the ROU assets recognised at date of initial application to be equal to their lease liabilities.

The Group is likely to elect the practical expedient not to reassess whether a contract contains a lease at the date of initial application, 1 April 2019. Accordingly, existing lease contracts that are still effective on 1 April 2019 continue to be accounted for as lease contracts under SB-FRS116. The Group has performed a preliminary assessment of the impact on its financial statements based on its existing operating lease arrangements.

Until 2018, the financial impact of the standard will be affected by factors that impact calculation of lease liabilities such as discount rate, expected term of leases including renewal options and exemptions for short-term leases. The Group will continue to assess its portfolio of leases to calculate the impending impact of transition to the new standard.

(i) The Group as lessee

The Group expects its existing operating lease arrangements to be recognised as ROU assets with corresponding lease liabilities under SB-FRS116. The operating lease commitments on an undiscounted basis amount to approximately 0.5% of the consolidated total assets and 0.9% of consolidated total liabilities. Under the new standard, remaining lease payments of the operating leases will be recognised at their present value discounted using appropriate discount rate. In addition, the nature of expenses related to those leases will now change as SB-FRS116 replaces the straight-line operating lease expense with depreciation charge of ROU assets and interest expense on lease liabilities.

(ii) The Group as lessor

SB-FRS116 substantially carries forward the current existing lessor accounting requirements. Accordingly, the Group continues to classify its leases as operating leases and to account for this type of leases using the existing operating lease. However, SB-FRS116 requires more extensive disclosures to be provided by a lessor.